Stock listing

TSXV:MRVL Marvel Biosciences Corp Stock

Home listing (TSXV) of Marvel Biosciences Corp

Follow Marvel Biosciences Corp into a list and get an email when it puts out news.

Share price · TSXV:MRVL

$0.115 CAD 0.000 (0.0%)

Close on Nov 20, 2026

Past year -32.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.115 – $0.115 CADNov 20, 2026
Volume
13,444 sharesNov 20, 2026
Market cap
$8.47M CADAt the close on Nov 20, 2026 · price × 73.68M shares outstanding
52-week range
$0.095 – $0.250 CADLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$10,760 CADMedian day 30,176 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Marvel Biosciences Corp logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
TSXV:MRVL · Home$0.115 CAD0.000 (0.0%)13,444$0.115$0.115$0.115$0.115Close on Nov 20, 2026
OTC:MBCOF$0.08 USD0.00 (0.0%)16,231$0.08$0.08$0.08$0.08Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · TSXV:MRVL · CAD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.1150.0000.0%$0.115$0.115$0.11513,444
$0.115-0.015-11.5%$0.130$0.130$0.11529,518
$0.1300.0000.0%$0.130$0.130$0.12515,085
$0.1300.0000.0%$0.135$0.135$0.13024,370
$0.130+0.005+4.0%$0.130$0.130$0.13012,731
$0.125+0.010+8.7%$0.130$0.130$0.12512,149
$0.115-0.005-4.2%$0.125$0.130$0.11575,200
$0.1200.0000.0%$0.115$0.120$0.11519,500
$0.1200.0000.0%$0.115$0.120$0.09579,606
$0.120+0.005+4.3%$0.120$0.120$0.11026,590
$0.115+0.005+4.5%$0.110$0.120$0.100252,068
$0.110-0.005-4.3%$0.115$0.115$0.11044,806
$0.115-0.005-4.2%$0.115$0.120$0.11531,666
$0.1200.0000.0%$0.120$0.120$0.1204,134
$0.1200.0000.0%$0.120$0.120$0.1205,000
$0.1200.0000.0%$0.125$0.125$0.1205,569
$0.1200.0000.0%$0.125$0.125$0.12029,000
$0.120-0.005-4.0%$0.120$0.120$0.12085,605
$0.125+0.010+8.7%$0.120$0.125$0.11558,559
$0.1150.0000.0%$0.120$0.120$0.11530,833
$0.115-0.005-4.2%$0.125$0.125$0.115111,000
$0.1200.0000.0%$0.120$0.120$0.1202,109
$0.120+0.025+26.3%$0.095$0.120$0.095280,267
$0.095-0.005-5.0%$0.100$0.100$0.09527,525
$0.1000.0000.0%$0.105$0.110$0.10058,039
$0.100-0.010-9.1%$0.105$0.105$0.100118,800
$0.1100.0000.0%$0.110$0.110$0.10533,500
$0.110-0.005-4.3%$0.110$0.110$0.11053,258
$0.1150.0000.0%$0.110$0.120$0.11075,000
$0.115+0.010+9.5%$0.105$0.115$0.105148,996
$0.105-0.005-4.5%$0.120$0.120$0.10588,392
$0.1100.0000.0%$0.110$0.120$0.110177,779
$0.110-0.010-8.3%$0.120$0.120$0.105226,209
$0.120-0.030-20.0%$0.150$0.150$0.120474,666
$0.150-0.005-3.2%$0.155$0.155$0.15014,358
$0.1550.0000.0%$0.155$0.160$0.15527,118
$0.155+0.005+3.3%$0.145$0.155$0.145176,922
$0.1500.0000.0%$0.150$0.150$0.14521,841
$0.1500.0000.0%$0.150$0.150$0.1503,500
$0.1500.0000.0%$0.150$0.150$0.1505,400
$0.1500.0000.0%$0.150$0.150$0.14518,200
$0.1500.0000.0%$0.150$0.150$0.12051,805
$0.150+0.005+3.4%$0.145$0.150$0.1456,515
$0.1450.0000.0%$0.145$0.145$0.14515,578
$0.145-0.005-3.3%$0.145$0.150$0.14518,001
$0.1500.0000.0%$0.145$0.150$0.14510,066
$0.1500.0000.0%$0.150$0.150$0.145715,100
$0.1500.0000.0%$0.150$0.150$0.130730,716
$0.150+0.010+7.1%$0.150$0.150$0.12557,296
$0.1400.0000.0%$0.140$0.140$0.1401,600
$0.1400.0000.0%$0.145$0.145$0.14017,900
$0.140-0.010-6.7%$0.150$0.155$0.130149,374
$0.1500.0000.0%$0.150$0.150$0.15016,793
$0.1500.0000.0%$0.150$0.155$0.14043,596
$0.150-0.005-3.2%$0.150$0.150$0.15017,001
$0.155+0.005+3.3%$0.150$0.155$0.14536,014
$0.150-0.005-3.2%$0.150$0.150$0.15012,637
$0.155+0.005+3.3%$0.150$0.155$0.14582,926
$0.1500.0000.0%$0.155$0.155$0.14571,600
$0.1500.0000.0%$0.145$0.155$0.14570,333
$0.150-0.005-3.2%$0.155$0.155$0.15023,927
$0.155+0.005+3.3%$0.160$0.160$0.15519,610
$0.150-0.005-3.2%$0.165$0.165$0.15018,112
$0.155-0.010-6.1%$0.155$0.165$0.15544,356
Ticker
TSXV:MRVL
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
TSXV
Currency
CAD

What changed lately

Latest news

All Marvel Biosciences Corp news

Marvel Biosciences Corp on 6ix

Sector
Health care
Industry
Biotechnology
News releases
27 in the last 12 months · 101 in all · newest Nov 18, 2026 · oldest 2021
Decks
5 decks · latest February 2026

Where Marvel Biosciences Corp is listed

ListingExchangeCountryCurrency
TSXV:MRVL · Home listing · This pageTSXVCanadaCAD
Cboe Canada:MRVLCboe CanadaCanadaCAD
OTC:MBCOFOTCUnited StatesUSD

Valuation

Statements: 4 quarters to Apr 30, 2026 · price Nov 20, 2026

Enterprise value
$8.66M CAD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P/TSX Composite
0.91

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Marvel Biosciences Corp · TSXV:MRVLUS$5.91MUS$6.04Mn/an/an/an/an/an/a0.91
Kyntra Bio, Inc. · NASDAQ:KYNBUS$6.32M−US$33.97Mn/a−6.4×n/an/a−326.0%n/a1.58
Acurx Pharmaceuticals, Inc. · NASDAQ:ACXPUS$6.30M−US$3.35Mn/an/an/a0.9×n/a0.0×1.31
TrivarX Limited · ASX:TRIUS$6.11MUS$4.58Mn/an/an/a0.6×n/a0.0×n/a
Enveric Biosciences, Inc. · NASDAQ:ENVBUS$6.04MUS$429,455n/an/an/a1.1×n/a0.0×0.76
Medicofarma Biotech Spolka Akcyjna · NEWCONNECT:MDBUS$6.03MUS$6.03Mn/a314×n/a5.4×n/a0.0×n/a
Addex Therapeutics Ltd · SIX:ADXNUS$5.96MUS$5.13Mn/a68.2×n/a2.6×n/a0.0×n/a
Argenica Therapeutics Ltd · ASX:AGNUS$5.95MUS$1.74Mn/an/an/a1.5×n/a0.0×n/a
Exicure, Inc. · NASDAQ:XCURUS$5.89MUS$4.67Mn/an/an/a3.1×n/a0.0×0.49
Tempest Therapeutics, Inc. · NASDAQ:TPSTUS$5.74MUS$4.84Mn/an/an/an/an/an/a1.09
Oncotelic Therapeutics Inc · OTC:OTLCUS$5.58MUS$5.52M0.0×n/an/a0.0×n/a0.0×0.07
Median of the othersUS$5.99MUS$4.62M0.0×68.2×1.3×−326.0%0.0×0.93

Team and board

Officers

OfficerRole
J. Roderick MathesonChief Executive Officer and Director
Harry NijjarChief Financial Officer, CPA, CMA
Mark WilliamsPresident, Chief Science Officer and Director

Board

DirectorRole
Babak PedramDirector
J. Roderick MathesonChief Executive Officer and Director
Mark WilliamsPresident, Chief Science Officer and Director
Neil A. JohnsonDirector
Randall SmallboneDirector

Events

Next results
Nov 26, 2026 (expected)

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (February 2026)Investor deck15 slidesFebruary 2026
Investor Presentation (December 2024)Investor deck18 slidesDecember 2024
Investor Presentation (December 2024)Investor deck19 slidesDecember 2024
Investor Presentation (May 2023)Investor deck29 slidesMay 2023
Investor Presentation (April 2022)Investor deck31 slidesApril 2022

Open Decks

Financings

RaiseDateIn US dollars
Private placement of units
Closed: C$1.6M raised · C$0.15 a unit · 1 warrant at C$0.2 for 12 months · Raymond James Ltd. +5
Dealers: Raymond James Ltd. (finder), Canaccord Genuity Corp. (finder), Research Capital Corporation (finder), Acumen Capital Finance Partners Limited (finder), Hampton Securities (finder), Leede Financial Inc. (finder)
Use of proceeds: Deposit for phase 1 clinical trials of lead compound MB-204, general and administrative expenses and general working capital
Sep 29, 2026US$1.13M
Unsecured convertible debentures
Closed: C$500,000 raised · C$0.17 · free to trade Aug 17, 2026
Use of proceeds: Drug formulation, toxicology studies and general working capital
Apr 17, 2026US$365,738
Warrant exercise of common share purchase warrants
Announced: Warrants at C$0.15
Oct 3, 2025
Private placement of units
Closed: C$1.02M raised · C$0.125 a unit · 1 warrant at C$0.175 for 24 months · Raymond James Ltd. +5
Dealers: Raymond James Ltd. (finder), Canaccord Genuity Corp. (finder), Acumen Capital Finance Partners Limited (finder), Wood Gundy (finder), Abinvest Corporation (finder), Abingdon Capital Corp. (finder)
Use of proceeds: Drug formulation, toxicology studies and general working capital
May 12, 2025
Private placement of common shares
Cancelled: C$1.94M–C$2.5M · C$0.15 a share · Abingdon Capital
Dealers: Abingdon Capital (finder)
Use of proceeds: Deposit for phase 1 clinical trials of lead compound MB-204, general and administrative expenses and general working capital
May 2, 2025US$1.35M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in CAD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue000000
Cost of revenue547.4K302.0K887.5K1.38M613.1K265.2K
Gross profit-547.4K-302.0K-887.5K-1.38M-613.1K-265.2K
Research and development547.4K302.0K887.5K1.38M
Selling, general and administrative920.8K913.4K1.41M1.17M1.25M1.02M
Operating income-1.25M-1.27M-2.25M-2.55M-1.10M-954.8K
Depreciation and amortization0152185413284
EBITDA-2.25M-2.55M-1.10M-954.4K
Interest expense268.0K114.0K38.4K0000
Income before tax-2.21M-1.65M-2.29M-2.55M-3.04M-955.7K
Income tax-151.8K-63.5K
Net income-2.21M-1.65M-2.29M-2.55M-3.04M-955.7K
Earnings per share, basic-0.04-0.04-0.06-0.07-0.09-0.03

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents128.9K345.8K556.6K593.2K2.39M224.8K
Receivables56.4K59.1K35.8K
Current assets326.7K491.3K672.4K913.5K2.47M295.6K171
Property, plant and equipment152337750
Total assets326.7K491.3K672.4K913.5K2.47M296.0K
Accounts payable1.50M1.35M1.21M262.1K1.56K94.2K50.7K
Current liabilities4.33M3.32M1.39M718.0K112.5K177.2K209.3K
Long-term debt1.71M1.00M
Total liabilities4.33M3.32M2.39M718.0K112.5K177.2K
Shareholders' equity-4.01M-2.83M-1.72M195.5K2.36M118.8K
Shares outstanding53.0M44.8M39.8M37.1M32.6M32.6M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-1.15M-1.18M-1.33M-2.19M-1.37M-538.5K-157.4K
Capital spending000000-1.03K
Free cash flow-1.15M-1.18M-1.33M-2.19M-1.37M-538.5K-158.4K
Cash from investing381.6K381.6K-1.03K
Cash from financing933.4K968.6K1.30M394.0K3.16M763.2K158.6K
Change in cash-216.9K-210.9K-36.6K-1.80M2.17M224.6K171

Open Financials

Cap table

Built by 6ix from Marvel Biosciences Corp’s releases · as of Sep 30, 2026

Common shares
73,682,588
Fully diluted
95,841,316

Fully diluted

LineSharesAs of
Common shares73,682,588Sep 29, 2026
Warrants22,099,035Sep 30, 2026
Options and RSUs59,693

Warrants and options

Lot
Warrants · C$0.20 · expire about Sep 2027
Warrants · C$0.18 · expire about Mar 2027
Broker warrants · expiry not stated
Broker warrants · C$0.20 · expiry not stated
Broker warrants · C$0.20 · expiry not stated
DSUs · expiry not stated

Share count over time

CountShares
Sep 29, 202673,682,588
Apr 30, 202663,028,290

Open Cap table

Shareholders

TradeTradeSharesPriceValueDate
Jacqueline Groot
Senior Officer of Issuer
Gift250,000CAD 0.16CAD 40,000Aug 19, 2026
Joseph Roderick Matheson
10% Security Holder of Issuer
Gift600,000CAD 0.16CAD 96,000Aug 19, 2026
Joseph Roderick Matheson
10% Security Holder of Issuer
Buy30,000CAD 0.16CAD 4,800Aug 14, 2026
Joseph Roderick Matheson
10% Security Holder of Issuer
Conversion4,166,667CAD 0.12CAD 500KFeb 24, 2026
Joseph Roderick Matheson
10% Security Holder of Issuer
Buy857,142CAD 0.14CAD 120KFeb 24, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Mark Williams
Other companies: TMX Group Ltd. (President and Chief Science Officer · Since at least Dec 22, 2025)
President, Chief Science Officer and Director · Since at least Oct 21, 2026
Babak PedramDirector · Since at least Nov 5, 2026
Harry NijjarChief Financial Officer, CPA, CMA · Since at least Nov 4, 2026
J. Roderick MathesonChief Executive Officer and Director · Since at least Oct 19, 2026
Neil A. JohnsonDirector · Since at least Jan 7, 2025
Randall SmallboneDirector · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Marvel Biosciences Corp.